Company intelligence / Profile preview
Chengdu Ori Pharmaceutical
Chengdu, Sichuan, Chinaori-bio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chengdu Ori-Bio Pharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of innovative peptide-based therapeutics for metabolic and endocrine diseases. The company leverages its proprietary peptide engineering platform to create long-acting and multi-targeting analogs, particularly focusing on GLP-1, GIP, and Glucagon receptor agonists. Their lead programs target high-prevalence conditions such as type 2 diabetes, obesity, and MASH (NASH). Ori-Bio aims to improve patient outcomes through enhanced efficacy and better tolerability profiles compared to existing treatments.
- Therapeutic areas
- EndocrinologyGastroenterologyMetabolic Disorders
- Modalities
- PeptidesBiologicSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Chengdu Ori Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Ori Pharmaceutical.